Will mTOR inhibitors make it as cancer drugs?

Cancer Cell. 2003 Nov;4(5):343-8. doi: 10.1016/s1535-6108(03)00275-7.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Carcinoma, Renal Cell / drug therapy
  • Carcinoma, Renal Cell / metabolism
  • Carrier Proteins / metabolism
  • Clinical Trials as Topic
  • Enzyme Inhibitors / pharmacology
  • G1 Phase
  • Humans
  • Insulin-Like Growth Factor I / metabolism
  • Kidney Neoplasms / drug therapy
  • Kidney Neoplasms / metabolism
  • Phosphoproteins / metabolism
  • Phosphorylation
  • Protein Biosynthesis / physiology
  • Protein Kinase Inhibitors
  • Protein Kinases / metabolism*
  • Ribosomal Protein S6 Kinases / metabolism
  • Signal Transduction / physiology*
  • Sirolimus / pharmacology
  • TOR Serine-Threonine Kinases
  • Tacrolimus Binding Protein 1A / metabolism

Substances

  • Adaptor Proteins, Signal Transducing
  • Carrier Proteins
  • EIF4EBP1 protein, human
  • Enzyme Inhibitors
  • Phosphoproteins
  • Protein Kinase Inhibitors
  • Insulin-Like Growth Factor I
  • Protein Kinases
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Ribosomal Protein S6 Kinases
  • Tacrolimus Binding Protein 1A
  • Sirolimus